Overview
One of the most instructive failures in neurology. Davunetide had a clean mechanism, encouraging phase 2 data, and a well-designed phase 3 trial in a tau disease — and it did nothing. Any peptide marketed for cognition should be measured against this outcome.
Investigational — not approvedInvestigational; development for the primary indication discontinued.
| Regulatory status | Failed a phase 3 trial in progressive supranuclear palsy in 2012. Later explored for ADNP syndrome. Not approved. |
|---|---|
| Drug class | Eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) |
| Route | Intranasal or intravenous (investigational) |
| Half-life | Short; designed for CNS penetration |
| Evidence rating |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
Small or early-phase human trials, or good controlled topical human data. |
| Studied in | Phase 2 in amnestic mild cognitive impairment and schizophrenia; a large randomized phase 3 trial in progressive supranuclear palsy; later work in ADNP syndrome. |
How it works
Derived from ADNP, davunetide interacts with tubulin and microtubule end-binding proteins, stabilising the microtubule network. Because tau normally stabilises microtubules, the rationale was to substitute for tau function in diseases where tau is dysfunctional.
Evidence base
Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.
- A properly powered negative phase 3 trial — high-quality evidence of absence of effect.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Well-defined molecular mechanism Moderate evidence
Microtubule stabilisation via end-binding proteins is demonstrable and specific.
-
Encouraging phase 2 signals Moderate evidence
Early trials suggested cognitive benefit in mild cognitive impairment and in schizophrenia-associated functional measures.
-
Excellent safety profile Strong evidence
Well tolerated across trials including the large phase 3 — the failure was efficacy, not safety.
-
Rationale in ADNP syndrome Preliminary
In a rare disorder caused by ADNP mutation, replacing the fragment has a clearer mechanistic case than in sporadic disease.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Failed a well-designed phase 3 Serious
No benefit on any endpoint in progressive supranuclear palsy. This is the defining fact and it should temper enthusiasm for the whole neuroprotective peptide category.
-
Phase 2 signals did not replicate Serious
A textbook example of early cognitive signals disappearing under proper power and blinding.
-
Not available Moderate evidence
No approved product and no lawful supply.
-
Nasal irritation Minor
Reported with the intranasal formulation.
Who should avoid it
- Not applicable — no lawful supply exists
If used under medical supervision, monitor
- Not applicable
Regulatory & legal status
Investigational; development for the primary indication discontinued.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Davunetide
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Cognitive & Neurological
Terms used on this page
- Phase 3 Trial
- A Phase 3 trial is the large confirmatory study, powered for a prespecified clinical endpoint, on which a marketing application and the resulting product label are built.
- Phase 2 Trial
- A Phase 2 trial is the first test of a compound in the target patient population, sized to find a workable dose and an early efficacy signal rather than to prove clinical benefit.
- Neuroprotection
- Neuroprotection is any intervention intended to preserve neurons from an ongoing insult, rather than to relieve symptoms, and it is the field with the widest gap between animal and human results.
- Blinding
- Blinding is the withholding of treatment-assignment knowledge from participants, clinicians, outcome assessors or analysts, so that expectation and behaviour cannot bias what a trial measures.
- Intranasal Delivery
- Intranasal delivery uses the nasal mucosa as an absorption surface, offering needle-free administration and rapid onset but low and variable bioavailability for peptides.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.